CSL889 for sickle cell pain crisis
Part of Blood & lymphatic, Genetic & congenital, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a new medicine, CSL889, for people with sickle cell disease who are currently having a pain crisis (vaso-occlusive crisis). The goal is to see if it safely helps reduce the pain and speed recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older and have sickle cell disease of any type.
- You are at the hospital now with a new pain crisis that needs strong pain medicine through an IV.
- Your pain started less than 72 hours ago before your first IV pain medicine.
- You have not had more than 5 pain crises requiring hospital stays in the last 6 months.
- You do not have signs of acute chest syndrome, a recent stroke, or new kidney injury.
- You are not currently taking methadone or buprenorphine for pain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an intravenous medicine called L-citrulline for young people with sickle cell disease who are in the emergency department for a painful crisis (vaso-occlusive crisis). It aims to see if it can ease the pain and help you recover faster.
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
This trial tests whether a numbing medicine (lidocaine) given through a vein can help reduce the amount of strong painkillers (morphine or oxycodone) needed for a sickle cell pain crisis or acute chest syndrome. It aims to ease pain and possibly lower side effects from opioids.
This trial tests if an intravenous medication called L-citrulline can help treat pain crises in children and young adults with sickle cell disease. Participants receive either the study drug or a placebo while in the hospital for a severe pain episode.
This trial compares different ways to manage sickle cell pain crises in the hospital, using a flexible 'platform' design to test combinations of pain medicines. It aims to find the safest and most effective approach to reduce pain and improve recovery.
This trial tests CS-206, an experimental therapy for people with sickle cell disease. It aims to reduce severe complications like pain crises, acute chest syndrome, strokes, and other serious events. You may qualify if you have a specific genetic type of sickle cell disease and have experienced complications despite standard treatments.
Hear when a new Sickle Cell Disease Vaso-occlusive Crisis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.